Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: A randomized, double-blind, placebo-controlled trial

American Journal of Kidney Diseases

Volumn 60, Issue 6, 2012, Pages 896-903

  Fallahzadeh, Mohammad Kazem ^a,b   Dormanesh, Banafshe ^a   Sagheb, Mohammad Mahdi ^b   Roozbeh, Jamshid ^b   Vessal, Ghazal ^b   Pakfetrat, Maryam ^b   Daneshbod, Yahya ^c   Kamali Sarvestani, Eskandar ^d   Lankarani, Kamran B ^e  

^a AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Dr Daneshbod Laboratory   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetic nephropathy; flavonoids; inflammation; milk thistle; oxidative stress; silymarin

Indexed keywords

ACARBOSE; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLITAZONE DERIVATIVE; INSULIN; LOSARTAN; MALONALDEHYDE; PLACEBO; SILYMARIN; SULFONYLUREA DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOATING; BLOOD LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINE LEVEL;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; SILYMARIN; TREATMENT OUTCOME;

EID: 84868704907     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.06.005     Document Type: Article

References (41)

1. E. Ritz, I. Rychlik, F. Locatelli, S. Halimi End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions Am J Kidney Dis 34 5 1999 795 808
2. R.Z. Ting, A.O. Luk, J.C. Chan Treatment and landmark clinical trials for renoprotection Contrib Nephrol 170 2011 184 195
3. A.E. Decleves, K. Sharma New pharmacological treatments for improving renal outcomes in diabetes Nat Rev Nephrol 6 6 2010 371 380
4. A. Luk, J.C. Chan Diabetic nephropathy - what are the unmet needs? Diabetes Res Clin Pract 82 suppl 1 2008 S15 S20
5. F. Turgut, W.K. Bolton Potential new therapeutic agents for diabetic kidney disease Am J Kidney Dis 55 5 2010 928 940
6. J.F. Navarro-Gonzalez, C. Mora-Fernandez, M. Muros de Fuentes, J. Garcia-Perez Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy Nat Rev Nephrol 7 6 2011 327 340
7. D.K. Singh, P. Winocour, K. Farrington Oxidative stress in early diabetic nephropathy: fueling the fire Nat Rev Endocrinol 7 3 2011 176 184
8. L. Abenavoli, R. Capasso, N. Milic, F. Capasso Milk thistle in liver diseases: past, present, future Phytother Res 24 10 2010 1423 1432
9. C. Bokemeyer, L.M. Fels, T. Dunn Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity Br J Cancer 74 12 1996 2036 2041
10. J. Gaedeke, L.M. Fels, C. Bokemeyer, U. Mengs, H. Stolte, H. Lentzen Cisplatin nephrotoxicity and protection by silibinin Nephrol Dial Transplant 11 1 1996 55 62
11. G. Kaur, M. Athar, M.S. Alam Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response Invest New Drugs 28 5 2010 703 713
12. J. Sonnenbichler, F. Scalera, I. Sonnenbichler, R. Weyhenmeyer Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells J Pharmacol Exp Ther 290 3 1999 1375 1383
13. G. Vessal, M. Akmali, P. Najafi, M.R. Moein, M.M. Sagheb Silymarin and milk thistle extract may prevent the progression of diabetic nephropathy in streptozotocin-induced diabetic rats Ren Fail 32 6 2010 733 739
14. C. Soto, J. Perez, V. Garcia, E. Uria, M. Vadillo, L. Raya Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus Phytomedicine 17 14 2010 1090 1094
15. M. Saghaei Random allocation software for parallel group randomized trials BMC Med Res Methodol 4 2004 26
16. A. Levey, T. Greene, J. Kusek, G. Beck, M.S. Group A simplified equation to predict glomerular filtration rate from serum creatinine [abstract] J Am Soc Nephrol 11 9 2000 155A
17. P. Khajehdehi, M. Pakfetrat, K. Javidnia Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study Scand J Urol Nephrol 45 5 2011 365 370
18. J. Roozbeh, M.A. Banihashemi, M. Ghezlou Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy Ren Fail 32 2 2010 172 178
19. J.F. Navarro, C. Mora, M. Muros, J. Garcia Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients Nephrol Dial Transplant 21 12 2006 3428 3434
20. J.F. Navarro, C. Mora, M. Gomez, M. Muros, C. Lopez-Aguilar, J. Garcia Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients Nephrol Dial Transplant 23 3 2008 919 926
21. J.F. Navarro, C. Mora, M. Maca, J. Garca Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus Am J Kidney Dis 42 1 2003 53 61
22. J. Schumann, J. Prockl, A.K. Kiemer, A.M. Vollmar, R. Bang, G. Tiegs Silibinin protects mice from T cell-dependent liver injury J Hepatol 39 3 2003 333 340
23. D. Chandler, A. Woldu, A. Rahmadi Effects of plant-derived polyphenols on TNF-alpha and nitric oxide production induced by advanced glycation endproducts Mol Nutr Food Res 54 suppl 2 2010 S141 S150
24. C.F. Bannwart, J.C. Peracoli, E. Nakaira-Takahagi, M.T. Peracoli Inhibitory effect of silibinin on tumour necrosis factor-alpha and hydrogen peroxide production by human monocytes Nat Prod Res 24 18 2010 1747 1757
25. C. Morishima, M.C. Shuhart, C.C. Wang Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection Gastroenterology 138 2 2010 671 681 681 e671-e672
26. F. Nazemian, G. Karimi, M. Moatamedi, S. Charkazi, J. Shamsara, A.H. Mohammadpour Effect of silymarin administration on TNF-alpha serum concentration in peritoneal dialysis patients Phytother Res 24 11 2010 1654 1657
27. C.H. Wu, S.M. Huang, G.C. Yen Silymarin: a novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo Antioxid Redox Signal 14 3 2011 353 366
28. J.F. Navarro, C. Mora, M. Muros, J. Garcia Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial J Am Soc Nephrol 16 7 2005 2119 2126
29. J.F. Navarro, C. Mora, A. Rivero Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration Am J Kidney Dis 33 3 1999 458 463
30. A. Rashidi, M. Nakhjavani, A. Esteghamati Association between oxidant/antioxidant markers and proteinuria in type 2 diabetes: results in 142 patients J Nephrol 22 6 2009 733 738
31. T. Cvetkovic, B. Mitic, G. Lazarevic, P. Vlahovic, S. Antic, V. Stefanovic Oxidative stress parameters as possible urine markers in patients with diabetic nephropathy J Diabetes Complications 23 5 2009 337 342
32. J.M. Chang, M.C. Kuo, H.T. Kuo, Y.W. Chiu, H.C. Chen Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy J Lab Clin Med 146 4 2005 210 215
33. M. Velussi, A.M. Cernigoi, A. De Monte, F. Dapas, C. Caffau, M. Zilli Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients J Hepatol 26 4 1997 871 879
34. E.W. Rivarola, M. Moyses-Neto, M. Dantas, C.G. Da-Silva, R. Volpini, T.M. Coimbra Transforming growth factor beta activity in urine of patients with type 2 diabetes and diabetic nephropathy Braz J Med Biol Res 32 12 1999 1525 1528
35. L. Paczek, H.E. Kropiewnicka, G. Senatorski, I. Bartlomiejczyk [Urine TGF-beta1 concentration in patients with type II diabetes mellitus - prognostic values] Pol Arch Med Wewn 108 2 2002 745 752
36. R.E. Gilbert, A. Akdeniz, T.J. Allen, G. Jerums Urinary transforming growth factor-beta in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology Nephrol Dial Transplant 16 12 2001 2442 2443
37. P. Katavetin, S. Eiam-Ong, S. Suwanwalaikorn Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy J Med Assoc Thai 89 2 2006 170 177
38. D.H. Jeong, G.P. Lee, W.I. Jeong Alterations of mast cells and TGF-beta1 on the silymarin treatment for CCl(4)-induced hepatic fibrosis World J Gastroenterol 11 8 2005 1141 1148
39. J.D. Jia, M. Bauer, J.J. Cho Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1 J Hepatol 35 3 2001 392 398
40. H.F. Huseini, B. Larijani, R. Heshmat The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial Phytother Res 20 12 2006 1036 1039
41. S.A. Hussain Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes J Med Food 10 3 2007 543 547